Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bradykinin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Bradykinin. Displaying page 1 of 1.
    EudraCT Number: 2004-000333-10 Sponsor Protocol Number: GEN/231/51/BMcK/JCL Start Date*: 2004-12-15
    Sponsor Name:Research & Innovation Services, University of Dundee
    Full Title: The inhibitory effect of local anaesthetics on the G-protein-mediated vascular flare response to bradykinin and substance P
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-002225-29 Sponsor Protocol Number: AntagoBrad-Cov Start Date*: 2020-11-12
    Sponsor Name:Groupement de Coopération Sanitaire Ramsay Générale de Santé pour l’Enseignement et la Recherche
    Full Title: Evaluation of the effects of bradykinin antagonists on pulmonary manifestations of COVID-19 infections.
    Medical condition: COVID positive patients with respiratory impairment
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004848 10084437 COVID-19 PCR test positive LLT
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002339-24 Sponsor Protocol Number: NA Start Date*: 2012-05-25
    Sponsor Name:Barts and the London NHS Trust
    Full Title: Open label, single-centre study to evaluate the efficacy of the bradykinin (BK) B2 receptor antagonist, Icatibant, in the relief of symptoms resulting from moderate to severe angioedema unresponsiv...
    Medical condition: Idiopathic Angioedema
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-014918-99 Sponsor Protocol Number: BKOS-02 Start Date*: 2010-01-19
    Sponsor Name:Menarini Ricerche, S.p.A
    Full Title: Intra-articular treatment with MEN16132 in patients with symptomatic primary osteoarthritis of the knee: A randomised, multi-centre, double blind, placebo controlled, five parallel group, dose find...
    Medical condition: patients with symptomatic primary osteoarthritis of the knee
    Disease: Version SOC Term Classification Code Term Level
    12.0 10031165 Osteoarthritis knee LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-002805-21 Sponsor Protocol Number: D2530C00011 Start Date*: 2005-09-25
    Sponsor Name:AstraZeneca AB
    Full Title: A randomized, double-blind, placebo controlled, three-way crossover study exploring the efficacy of AZD3778 compared with placebo and an oral antihistamine (loratadine) in a model of seasonal aller...
    Medical condition: This is a Phase II trial (Proof of Principle) in volunteer rhinitis subjects utilising a seasonal model of rhinitis and challenge agent
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001540-71 Sponsor Protocol Number: JE049 #2102 Start Date*: 2005-07-23
    Sponsor Name:Jerini AG
    Full Title: Randomised, double blind, controlled, parallel group, multicentre study of a subcutaneous formulation of Icatibant vs. oral Tranexamic acid for the treatment of hereditary angioedema (HAE).
    Medical condition: Hereditary Angioedema (HAE)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) HU (Completed) AT (Completed) LT (Completed) IE (Completed) DE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019037-10 Sponsor Protocol Number: INITIAtE Start Date*: 2010-11-24
    Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
    Full Title: IcatibaNt In Treatment of Idiopathic Angio Edema.
    Medical condition: Idiopathic angioedema.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051379 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000757-93 Sponsor Protocol Number: ISIS721744-CS7 Start Date*: 2022-09-05
    Sponsor Name:IONIS PHARMACEUTICALS, INC.
    Full Title: An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
    Medical condition: Hereditary Angioedema (HAE)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10010331 - Congenital, familial and genetic disorders 10019860 Hereditary angioedema PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) NL (Ongoing) DK (Completed) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-001670-28 Sponsor Protocol Number: BER-1272-0058-I Start Date*: 2013-03-18
    Sponsor Name:Medizinische Fakultät der Technischen Universität München
    Full Title: Angiotensin Converting Enzyme Inhibitor (ACE) Induced Angioedema BERINERT Randomized, double-blind, two arms, multicenter, Phase III study of Berinert for treatment of ACE induced Angioedema
    Medical condition: Angiotensin – Converting – Enzyme – Inhibitors (ACEi) are used in the treatment of several types of cardiovascular and renal diseases. A known side effect of ACEi are angioedema of the head and ...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004870 10002425 Angioedemas HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001703-20 Sponsor Protocol Number: SHP643-303 Start Date*: 2020-08-28
    Sponsor Name:Dyax Corporation, a Takeda company
    Full Title: A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema wi...
    Medical condition: non-histaminergic angioedema with normal C1-INH and acquired angioedema due to C1-INH deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10002425 Angioedemas HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) PL (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-001739-28 Sponsor Protocol Number: S63979 Start Date*: 2020-05-20
    Sponsor Name:UZLeuven
    Full Title: A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19.
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10038700 Respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 23 18:36:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA